Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
Overview
10X Genomics, Inc. is a pioneering life science technology company that builds integrated systems to enable high-resolution analysis of biological systems. The company's suite of instruments, consumables, and software platforms are designed to empower researchers by unlocking the complex details of single cell biology and spatial transcriptomics. Through its advanced solutions, 10X Genomics facilitates breakthroughs in oncology, immunology, neuroscience, and other fields by allowing scientists to conduct experiments that dissect biological intricacies at an unprecedented scale and accuracy.
Integrated Solutions for Advanced Research
At the core of 10X Genomics’ approach is a commitment to providing comprehensive, integrated solutions. Their platforms merge state-of-the-art hardware with innovative software that enables both single cell analysis and spatial profiling of tissues. This combination of high-performance instrumentation with intuitive analytical tools equips researchers to unravel cellular heterogeneity and examine spatial relationships within tissues. These capabilities are essential for understanding disease mechanisms, drug responses, and the multifaceted nature of biological processes.
Core Technologies and Innovation
10X Genomics has established a strong reputation for its ability to translate complex biological queries into actionable information. Its technologies are built around a modular design that includes microfluidic systems, robust reagents, and dedicated software ecosystems. The company emphasizes the importance of achieving resolution and scale in biological analysis, ensuring that each cell, and even its spatial context, is captured in detail. Through continual innovation, the company has transformed conventional research approaches and provided researchers with tools to perform high-throughput experiments on a scale that was once considered unattainable.
Market Position and Research Impact
Positioned within the competitive landscape of life science technology, 10X Genomics stands out due to its focus on both single cell and spatial methodologies. Academic institutions, translational researchers, and biopharmaceutical companies rely on its accurate and high-resolution data to fuel discoveries that redefine our understanding of biology. The company’s products are integral to research initiatives that explore the underlying biology of diseases, aiding in the identification of novel biomarkers and therapeutic targets. Through its collaborative efforts with leading research institutions, the company continues to contribute to a growing body of scientific literature, thereby reinforcing its role as a key enabler of modern biological research.
Product Platforms and Applications
The multifaceted product portfolio of 10X Genomics is designed to meet the evolving needs of the life sciences community. The company’s instruments and consumables are optimized for experiments that require detailed analysis of RNA expression, genomic variation, and tissue architecture. These capabilities are not only instrumental in basic research settings but also in translational studies where precision and reproducibility are paramount. Researchers benefit from an ecosystem where each component—from reagent formulation to data analysis—is engineered to offer a seamless workflow, thereby accelerating the pace of scientific discovery.
Scientific Rigor and Data Quality
The technologies developed by 10X Genomics are backed by extensive validation and have been cited in a significant number of scientific publications. The company’s commitment to quality and precision is reflected in its ongoing efforts to refine instruments and protocols to capture the experimental complexity inherent in biological research. By maintaining high standards of reproducibility and data integrity, 10X Genomics not only supports reliable research outcomes but also fosters trust within the academic and commercial research communities.
Commitment to Democratizing Access
In addition to technical excellence, 10X Genomics is committed to democratizing access to cutting-edge research tools. By continuously driving down the cost per analysis and simplifying experimental workflows, the company is making sophisticated single cell and spatial analyses accessible across various scales—from pioneering labs in academic institutions to large biopharmaceutical operations. This focus on accessibility ensures that researchers at all stages can capitalize on high-resolution biological insights without compromising on quality or throughput.
Competitive Differentiators
What differentiates 10X Genomics from its peers is a combination of technological innovation, integrated system design, and a deep understanding of biological complexity. The company’s products are engineered with a dual emphasis on performance and ease-of-use, ensuring that researchers can operate at the forefront of technology without extensive technical hurdles. Furthermore, the capacity to perform experiments that capture both cellular individuality and spatial context provides a holistic view of biological systems that is unique in the market.
Experience and Expertise
With a strong scientific team and a rich history of technological milestones, 10X Genomics has positioned itself as an authority in the field of single cell and spatial biology. The company leverages its deep scientific expertise to continually push the boundaries of what is possible, empowering researchers to generate high-quality data and drive powerful discoveries. An extensive network of research collaborations and a history of impactful publications further solidify its reputation as a trusted partner in the journey to unlock the complexities of life.
Conclusion
In summary, 10X Genomics, Inc. offers a robust suite of tools that redefine the landscape of biological research. Its commitment to integrated, high-resolution analysis has transformed the way researchers interrogate biological systems, ultimately advancing our understanding of health and disease. With a clear focus on performance, innovation, and accessibility, the company is well-positioned to remain a cornerstone in the scientific community, delivering reliable solutions that meet the intricate demands of modern research.
10x Genomics (TXG), a leader in single cell and spatial biology, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host a conference call and webcast for analysts and investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
The financial results will be accessible through a news release on the company's website before the conference call. Interested parties can access the live audio webcast through the 'Investors' section at investors.10xgenomics.com, with a replay available for at least 45 days following the event.
10x Genomics (TXG) has secured a significant legal victory against Parse Biosciences through a consent agreement entered on February 25, 2025, in the U.S. District Court for the District of Delaware. Parse agreed to a worldwide permanent injunction preventing them from making, using, or selling their planned ATAC and ATAC-Multiome Single Cell products.
Parse has admitted that 10x's ATAC-seq patents are valid, enforceable, and infringed by Parse's use of ATAC-seq methods and compositions. The agreement was reached one week before the scheduled trial. While this resolves the ATAC-related dispute, litigation regarding Parse's gene expression products continues, with additional patents under appeal. The March 2025 trial for remaining patent infringement claims has been stayed pending these appeals.
10x Genomics (TXG) announced new product innovations at the AGBT General Meeting to enhance its leadership in single cell and spatial biology. The company revealed significant advancements across its platforms, including:
For Chromium platform: New plate-based workflows for GEM-X Flex enabling analysis of 700+ samples per run, with capacity to recover 8 million cells per chip. The company is also launching 10x Cloud Analysis for Large Studies to manage extensive datasets.
For Visium platform: Planned additions include Visium HD 3' for high-resolution spatial profiling, Visium HD Cell Segmentation for morphology-guided analysis, and Visium HD XL for larger tissue sections.
For Xenium platform: Introduction of RNA+Protein Multiomics capability, allowing simultaneous detection of RNA and proteins on the same slide, featuring seven modular subpanels covering up to 28 protein targets.
10x Genomics (Nasdaq: TXG), a pioneer in single cell and spatial biology, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, March 4, at 11:10 a.m. Eastern Time.
Investors and interested parties can access a live webcast of the discussion through the company's investor relations website at https://investors.10xgenomics.com/. The presentation will remain available for replay on the website for a minimum of 45 days following the event.
10x Genomics (TXG) reported Q4 and full year 2024 financial results, showing revenue declines and continued operating losses. Q4 revenue decreased 10% to $165.0 million, while full-year revenue fell 1% to $610.8 million. The company's gross margin improved to 67% in Q4 and 68% for the full year.
Operating expenses decreased 6% to $160.8 million in Q4, with an operating loss of $49.8 million. For the full year, operating loss improved to $194.6 million from $265.3 million in 2023. The company ended 2024 with $393.4 million in cash and marketable securities.
Looking ahead, 10x Genomics provided 2025 revenue guidance of $610-630 million, projecting 0-3% growth. The company expects double-digit growth in both Chromium reactions and spatial revenue at the midpoint of guidance.
Chan Zuckerberg Initiative (CZI) has launched the Billion Cells Project, collaborating with 10x Genomics and Ultima Genomics to create an unprecedented one billion cell dataset for advancing AI in biology. The project aims to enhance understanding of cellular behavior and gene function through large-scale data generation.
The initiative will utilize 10x Genomics' Chromium GEM-X technology for single-cell analysis and Ultima Genomics' UG 100™ platform for high-throughput sequencing. The dataset will include organisms such as mouse, zebrafish, and primary human cell models, focusing on gene regulation and function across organisms.
CZI plans to make all results open source and freely available to scientists worldwide. The project will leverage CZI's computing system, one of the largest dedicated to nonprofit life sciences research, to train new virtual cell models and derive insights from the vast dataset.
10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, has announced it will release its fourth quarter and full year 2024 financial results after market close on February 12, 2025. The company will hold a conference call and webcast for analysts and investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
The financial results will be available on the company's website before the conference call. Investors can access the live webcast through the 'Investors' section of 10x Genomics' website, where it will remain available for replay for at least 45 days following the event.
10x Genomics (TXG) has announced preliminary, unaudited results for Q4 and full year 2024. The company reported Q4 2024 revenue of ~$165.0 million, showing 9% sequential growth but a 10% year-over-year decrease. Full-year 2024 revenue reached ~$610.8 million, representing a 1% decrease from 2023.
Q4 breakdown shows Instruments revenue at $24.4 million (28% sequential growth, -37% YoY), Consumables revenue at $133.5 million (6% sequential growth, -5% YoY), and Services revenue at $7.1 million (12% sequential growth, +35% YoY). The company's cumulative instrument installations exceeded 7,000 units, including over 5,800 Chromium, 800 Visium, and 400 Xenium instruments. Cash position stood at approximately $393 million as of December 31, 2024.
10x Genomics (Nasdaq: TXG), a pioneer in single cell and spatial biology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Monday, January 13, at 7:30 a.m. Pacific Time.
The presentation will take the format of a fireside chat and will be accessible via live webcast through the 'Investors' section of 10x Genomics' website. For those unable to attend live, the webcast recording will remain available for replay for a minimum of 30 days following the event.
Bruker (BRKR) faces a permanent injunction in Delaware's U.S. District Court regarding its GeoMx products, following a patent infringement lawsuit by 10x Genomics. The Court will enter the injunction in January 2025, prohibiting Bruker from making, selling, or offering GeoMx Digital Spatial Profiler products in the United States.
The Court affirmed the $31 million damages from the November 2023 jury verdict, plus supplemental damages and interest. Notably, existing GeoMx users who installed instruments before November 18, 2023, can continue purchasing reagents for ongoing research. The jury found that the GeoMx products willfully infringed seven patents licensed to 10x Genomics by Prognosys.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
What is the primary focus of 10X Genomics, Inc.?
How do 10X Genomics' solutions benefit researchers?
What makes 10X Genomics' technology stand out in the market?
Who are the typical customers of 10X Genomics?
In which research areas are 10X Genomics' products widely used?
How does 10X Genomics ensure data quality and reproducibility?
What role does innovation play in the company’s strategy?
How does 10X Genomics support democratization of advanced research tools?
